Bone Density on a GLP-1: The Trial That Compared It Against Exercise

One randomized trial put the question directly: after losing weight, does it matter how you keep it off, as far as your bones are concerned? Adults with obesity spent eight weeks on a very low calorie diet, then a year on exercise, liraglutide, both, or placebo. Liraglutide alone lost bone mineral density at the hip and spine relative to exercise. The combination held bone density level with placebo while producing the largest weight loss of the four groups.^[1]

The four-arm trial

One hundred and ninety-five adults aged 18 to 65 with a BMI between 32 and 43, none of them diabetic, completed an eight-week 800 kcal/day diet and were then randomized for 52 weeks to a moderate-to-vigorous exercise program, liraglutide 3.0 mg daily, both, or placebo. Bone mineral density at hip, lumbar spine and distal forearm was measured by DXA from before the diet to the end of treatment.^[1]

Now the bone results, which do not follow the weight results. Against placebo, the combination group’s bone mineral density was unchanged at the hip (−0.006 g/cm², P = .24) and lumbar spine (−0.010 g/cm², P = .20) — despite that group losing more than twice as much weight. Against exercise, liraglutide alone decreased bone density at the hip (−0.013 g/cm², P = .03) and spine (−0.016 g/cm², P = .04).^[1]

The arm that lost the most weight was not the arm that lost the most bone. What separated them was the exercise.

And a meta-analysis that points the other way

A 2025 systematic review pooled 25 randomized trials in people with type 2 diabetes and found the opposite direction. GLP‑1 receptor agonists came out superior to control on lumbar spine BMD (+0.07 g/cm²), hip neck BMD (+0.05) and total hip BMD (+0.06), all highly significant, with no significant increase in fracture risk (RR 0.80, 95% CI 0.47–1.36).^[2]

Both results are real and they are not measuring the same thing. The trial studied people without diabetes and compared the drug against exercise. The meta-analysis studied people with diabetes and compared against control. Diabetes itself damages bone quality, and improving glucose control plausibly helps it; in someone without diabetes there is no such deficit to repair, and what remains is the bone loss that accompanies losing weight.

What follows from it

• The trial's practical message is not about the drug, it is about the exercise: the arm combining both held bone density while losing the most weight.
• Resistance and weight-bearing exercise is the intervention with randomized support here, which is the same conclusion the muscle literature reaches.
• Neither source found an increase in fractures. The meta-analysis looked and found none.
• If you have type 2 diabetes, the pooled evidence in your population points toward benefit rather than harm.
• ⚠ Bone density is one input to fracture risk, not the whole of it. Whether you need a DXA scan is a clinical judgment, and this article does not make it.

Our companion page on bone density and fracture risk covers the fracture question in its own right, and what the body-composition studies measured sets out the parallel finding for muscle — where resistance training is again the only intervention with randomized backing.